Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
JAMA Dermatol 2023 May 03;[EPub Ahead of Print], MJ Zirwas, ZD Draelos, J DuBois, LH Kircik, AY Moore, L Stein Gold, J Alonso-Llamazares, M Bukhalo, S Bruce, K Eads, LJ Green, ST Guenthner, LK Ferris, SB Forman, SE Kempers, E Lain, CW Lynde, DM Pariser, DP Toth, PS Yamauchi, RC Higham, D Krupa, P Burnett, DR BerkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.